Submission of updated draft pre-consultation business case (PCBC) to NHS England for assurance

Since December we have been working with a wide range of experts, partners, local authority and public health colleagues, clinicians, the public and our regulators to gather research and evidence to help shape our proposals for Epsom and St Helier Hospitals.

This information has been used to update our draft pre-consultation business case. This information has been published on our website and includes:

  • Independent analysis of feedback from the public engagement activities;
  • The independent Clinical Senates of London and the South East report;
  • Phase 2 draft interim Integrated Impact Assessment; and
  • Impact on other providers – a summary assessment

We have now reached the stage where we have submitted our updated draft pre-consultation business case to NHS England so they can assess all of the information and agree if there would be funding in principle for a new facility in our area. The pre-consultation business case is a technical document that provides our national regulators with all of the evidence they need to assess our proposals.

We are not releasing the updated draft PCBC document at this time as we intend to do this when we have received national feedback and assurance signalling that we can move to consultation with the public.

No decisions about any changes to services will be made until after a full public consultation has taken place and all of the information – including, for example, any feedback from a formal public consultation and the final Integrated Impact Assessment – has been considered by the CCGs.

We have produced a stakeholder briefing document which explains what we have been doing and our current thinking. It is not a consultation document. The evidence and position set out in this briefing is subject to change as further evidence is developed and assurance by NHS England takes place. In particular, this briefing does not include detailed underlying financial information, as this is subject to assurance and regulatory oversight and is therefore not appropriate to publish at this stage.

Read our stakeholder briefing document – here.